FGL1 and metabolic dysfunction-associated steatotic liver disease: Among those, previous studies suggested that the induction of fibrinogen‐like 1 (FGL1)/hepassocin during MASLD contributed to disease progression, insulin resistance, and hyperglycemia [9, 10, 11].